Collaboration Tackles Critical Gaps in US STI Diagnostics
Intermountain Health’s support accelerates Testmate’s deployment of rapid molecular tests where patients often face delayed results or no access to lab-quality testing
Lausanne, Switzerland — December 4, 2025 — Intermountain Health and Testmate Health have announced a strategic partnership and investment to accelerate access to rapid, low-cost molecular tests for sexually transmitted infections (STIs) in the US. This collaboration positions Intermountain Health and Testmate Health to bring lab-quality STI diagnostics to at risk communities.
STIs remain a largely silent epidemic, with 80 percent of chlamydia and gonorrhea infections going undiagnosed each year. Populations most affected include college students, LGBTQ+ communities, and rural or low-resource clinics face significant barriers to timely testing and treatment. This partnership and investment directly address that gap by bringing high-accuracy, low-cost diagnostics to the people and places that need them most.
“Our partnership and investment in Testmate reflects our commitment to solutions that make care faster, more accessible, and equitable,” said Karen Brownwell, vice president of lab services at Intermountain Health.
“When these STI tests become FDA-approved in the US, Testmateʼs innovative approach to molecular diagnostics will allow us to deliver lab-quality results outside traditional lab settings, directly impacting communities that have historically lacked access to timely testing,” she added.
Testmateʼs single-use, reader-free molecular test for Chlamydia trachomatis and Neisseria gonorrhoeae, are able to deliver lab-quality results in under 30 minutes without central lab infrastructure. The molecular tests are easy to use and compatible with both urine and swab samples, enabling rapid, private, and stigma-free testing.
“This partnership and investment empowers people to take control of their sexual and reproductive health without barriers, stigma, or waiting,” said Dr. Siew-Veena Sahi, CEO & founder of Testmate Health. “By partnering with Intermountain Health, we could scale access to diagnostics in a way that changes outcomes for patients and communities alike.”
By combining Testmateʼs physician-built diagnostics with Intermountainʼs infrastructure and clinical expertise, the program will dramatically increase early detection, improve treatment, reduce loss to follow-up, and lower healthcare costs.